Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Risk factors for oligodendroglial tumors: a pooled international study.

McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, Feychting M, Il'yasova D, Inskip PD, Johansen C, Melin BS, Ruder AM, Butler MA, Scheurer ME, Schüz J, Schwartzbaum JA, Wrensch MR, Davis FG.

Neuro Oncol. 2011 Feb;13(2):242-50. doi: 10.1093/neuonc/noq173. Epub 2010 Dec 10.

2.

SWI/SNF gene variants and glioma risk and outcome.

Amankwah EK, Thompson RC, Nabors LB, Olson JJ, Browning JE, Madden MH, Egan KM.

Cancer Epidemiol. 2013 Apr;37(2):162-5. doi: 10.1016/j.canep.2012.12.001. Epub 2012 Dec 29.

3.

Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.

Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C.

Neuro Oncol. 2009 Jun;11(3):311-7. doi: 10.1215/15228517-2008-105. Epub 2008 Dec 9.

4.

Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.

Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR.

Clin Neuropathol. 2009 Jan-Feb;28(1):11-20. Erratum in: Clin Neuropathol. 2009 Mar-Apr;28(2):150.

PMID:
19216215
5.

The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.

Smith SF, Simpson JM, Brewer JA, Sekhon LH, Biggs MT, Cook RJ, Little NS.

J Neurooncol. 2006 Oct;80(1):75-82. Epub 2006 Jun 23.

PMID:
16794749
6.

Time trends in oligodendroglial and astrocytic tumor incidence.

McCarthy BJ, Propp JM, Davis FG, Burger PC.

Neuroepidemiology. 2008;30(1):34-44. doi: 10.1159/000115440. Epub 2008 Feb 6.

PMID:
18259099
7.

Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report.

Achey RL, Khanna V, Ostrom QT, Kruchko C, Barnholtz-Sloan JS.

J Neurooncol. 2017 May;133(1):17-25. doi: 10.1007/s11060-017-2414-z. Epub 2017 Apr 10.

PMID:
28397028
8.

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ.

Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011.

9.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

10.

Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.

Bauman GS, Cairncross JG.

Semin Radiat Oncol. 2001 Apr;11(2):170-80. Review.

PMID:
11285555
11.
12.

Polymorphous oligodendroglioma of Zülch revisited: a genetically heterogeneous group of anaplastic gliomas including tumors of bona fide oligodendroglial differentiation.

Hewer E, Beck J, Murek M, Kappeler A, Vassella E, Vajtai I.

Neuropathology. 2014 Aug;34(4):323-32. doi: 10.1111/neup.12097. Epub 2014 Jan 21.

PMID:
24444336
13.

Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.

Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G.

Brain Pathol. 2004 Apr;14(2):121-30.

PMID:
15193024
15.

Clinicopathological study of oligodendroglial tumors: the effectiveness of interferon beta, ACNU/MCNU, and radiation (IAR/IMR) for anaplastic tumors.

Wakabayashi T, Kajita Y, Hatano N, Thompson T, Nagasaka T, Yoshida J.

Brain Tumor Pathol. 2000;17(1):29-33.

PMID:
10982007
16.

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31.

17.

Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.

Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T.

Clin Cancer Res. 2002 Jan;8(1):196-201.

18.

Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.

Emblem KE, Scheie D, Due-Tonnessen P, Nedregaard B, Nome T, Hald JK, Beiske K, Meling TR, Bjornerud A.

AJNR Am J Neuroradiol. 2008 Oct;29(9):1664-70. doi: 10.3174/ajnr.A1182. Epub 2008 Jun 26.

19.

History of allergies and autoimmune diseases and risk of brain tumors in adults.

Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD.

Int J Cancer. 2002 May 10;99(2):252-9.

20.

Leptomeningeal disease in oligodendroglial tumors: a population-based study.

Roldán G, Chan J, Eliasziw M, Cairncross JG, Forsyth PA.

J Neurooncol. 2011 Sep;104(3):811-5. doi: 10.1007/s11060-011-0551-3. Epub 2011 Mar 4.

Supplemental Content

Support Center